在急性静脉血栓栓塞症患者的基线血小板计数和长期临床结果:前性队列研究

相关实验视频

Updated: Jun 13, 2025

06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

810

Johann Stuby¹, Odile Stalder², Andreas Limacher²

¹Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. johann.stuby@insel.ch.

Annals of hematology

|September 9, 2024

概括

急性静脉血栓塞栓症 (VTE) 的异常血小板计数 (PC) 是常见的,但它们的长期结局联系尚不清楚. 这项研究发现,基线PC与大出血,复发性VTE或VTE患者的死亡率之间没有一致的关联.

科学领域:

血液学血液学血液学
心血管医学心血管医学
临床研究临床研究

背景情况:

异常的血小板计数 (PC) 经常在急性静脉血栓栓塞 (VTE) 患者中观察到.
基线PC对VTE长期临床结果的预后意义尚未得到充分确立.
了解这种关系对于风险分层和患者管理至关重要.

研究的目的:

调查基线血小板计数 (PC) 与长期严重出血 (MB) 风险,复发性VTE和整体死亡率之间的关联.
在预期的VTE队列中,分析基线PC的不同类别中的这些风险.
提供关于PC在VTE管理中的临床相关性的见解.

主要方法:

对991名被诊断患有急性VTE的患者进行前性队列研究.
患者被分为四个基线PC组:非常低 (<100G/l),低 (≥100至<150G/l),正常 (≥150至≤450G/l) 和高 (>450G/l).
包括MB,复发性VTE和整体死亡率在内的结果在30个月的中位数随访期间进行了评估,并对混因素和相应风险进行了统计调整.

主要成果:

总共有132名 (13%) 患者经历了MB,122名 (12%) 患有复发性VTE,206人 (21%) 死亡.
低PC患者的VTE复发风险增加了两倍 (SHR为2.05,95%CI为1.28-3.28).
在多变量调整后,没有发现非常低或高的PC和严重出血之间,也没有发现低/非常低的PC和死亡率之间的一致关联.

结论:

该研究没有发现基线血小板计数与严重出血,复发性VTE或急性VTE患者的整体死亡率之间的一致关系.
虽然低血小板计数可能与VTE复发增加有关,但VTE基线PC的整体预后值似乎有限.
可能需要进一步的研究,以探索其他影响VTE患者随着血小板数量的变化而影响结果的因素.

关键词:

流血出血流血出血死亡率死亡率死亡率血小板是血小板的组成部分.复发情况复发情况静脉血栓塞栓症是一种静脉血栓塞栓症.

相关概念视频

01:22

Formation of the Platelet Plug

5.3K

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

5.3K

01:18

Structure and Function of Platelets

1.1K

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

1.1K

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

652

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

652

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

499

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

499

01:24

Disorders of Hemostasis

740

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

740